Hungarian National Systemic Amyloidosis Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSemmelweis University
About this trial
This registry is an observational, multicenter, retrospective and prospective, non-pharmacological study designed to collect and analyze data from patients with systemic amyloidosis treated in inpatient and outpatient cardiology, hematology, nephrology, and neurology departments across Hungary. The registry was established in 2025.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of systemic amyloidosis
Patients aged ≥18 years at the time of enrollment
Signed informed consent form by the patient
Treating physician's consent
Disqualifiers
Lack of informed consent in the prospective study
Trial population
Patients diagnosed with systemic amyloidosis in Hungary
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
300 Participants
are grouped into 1 trial groupGroup A: Systemic Amyloidosis Patients
Trial outcomes
Primary outcomes
1
Sex of Participants at Diagnosis
Sex (male or female as recorded in the medical record) of participants at the time of systemic amyloidosis diagnosis
Time frame
Baseline2
Age at Diagnosis
Age of participants in years at the time of systemic amyloidosis diagnosis
Time frame
Baseline3
Place of Residence at Diagnosis (Postal Code Level)
Participant place of residence recorded at the time of systemic amyloidosis diagnosis, reported at postal code (ZIP code) level. No street-level address information will be collected
Time frame
Baseline4
Treating Institution at Diagnosis
Healthcare institution where the participant received the initial diagnosis of systemic amyloidosis
Time frame
BaselineSecondary outcomes
1
Mortality
Annual mortality rate
Time frame
3 years2
Hospitalization
Annual hospitalization rate
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov